CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 92 target
Drug / intervention
Glecaprevir/pibrentasvir +1 moredrug
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Age 19-70 years
  • ✓Weight at least 45 kg
  • ✓Diagnosed with PTSD confirmed by CAPS-5 within seven days of enrollment
  • ✓Eligible for Veterans Affairs healthcare
Key exclusion· 14
  • ✕Pregnant or lactating
  • ✕Moderate or severe hepatic impairment (Child-Pugh B or C)
  • ✕History of prior hepatic decompensation
  • ✕Current use of drugs with significant interactions per prescribing label

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05637879
NCT05637879Phase 3RecruitingUpdate OverdueUpdated 14mo ago · Completion was 6mo ago
Enrollment Stalled
Update Overdue
CompareCT.gov

Randomized Controlled Trial of Glecaprevir/Pibrentasvir for the Treatment of Post-traumatic Stress Disorder

White River Junction Veterans Affairs Medical Center·interventional·Posted Dec 6, 2022·Updated Apr 24, 2025

In Brief

A Phase 3 clinical trial evaluating Glecaprevir/pibrentasvir and Placebo for PTSD. Currently recruiting, targeting 92 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD
CountriesUnited States
Collaborators--

Timeline

Phase 3Recruiting
2023202420252026
First PostedDec 6, 2022
Enrollment StartDec 18, 2023
Primary CompletionDec 31, 2025
Study CompletionSep 30, 2026
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.6 years ago

Interventions

Glecaprevir/pibrentasvirdrug

Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection

Placeboother

Compounded, inactive pill equal in appearance to active study drug